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Most of the new chemical entities (NCEs) are poorly water-soluble and pose a chal-
lenge to developing an optimum solid oral dosage form. Oral route has been the major
route of drug delivery for the treatment of various diseases. Delivery of poorly water-
-soluble molecules by oral route is difficult because approximately 40 % of drug com-
pounds are limited to low aqueous solubility, which leads to restricted oral bioavailabi-
lity, high intra- and inter-subject variability and lack of dose proportionality (1).
To increase the oral bioavailability of poorly water-soluble compounds and elimi-
nate the discussed drawbacks, various other formulation strategies have been adopted,
including the use of cyclodextrins, nanoparticles, solid dispersions and permeation en-
563
Acta Pharm. 62 (2012) 563–580 Original research paper
DOI: 10.2478/v10007-012-0031-0
Formulation development of an albendazole self-emulsifying








2 Drug Metabolism and Pharmacokinetics
Jubilant Biosys Ltd, Industrial Suburb,
Yeshwanthpur
Bangalore-560022, India
Accepted July 25, 2012
The aim of the study was to develop and evaluate a self-
-emulsifying drug delivery system (SEDDS) formulation
to improve solubility and dissolution and to enhance sys-
temic exposure of a BCS class II anthelmetic drug, alben-
dazole (ABZ). In the present study, solubility of ABZ was
determined in various oils, surfactants and co-surfactants
to identify the microemulsion components. Pseudoternary
phase diagrams were plotted to identify the microemulsi-
fication existence area. SEDDS formulation of ABZ was pre-
pared using oil (Labrafac Lipopfile WL1349) and a surfac-
tant/co-surfactant (Tween 80/PEG 400) mixture and was
characterized by appropriate studies, viz., microemulsify-
ing properties, droplet size measurement, in vitro dissolu-
tion, etc. Finally, PK of the ABZ SEDDS formulation was
performed on rats in parallel with suspension formula-
tion. It was concluded that the SEDDS formulation ap-
proach can be used to improve the dissolution and sys-
temic exposure of poorly water-soluble drugs such as ABZ.
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hancers (2, 3). In recent years, considerable attention has been focused on lipid-based
formulations to improve the oral bioavailability of poorly water-soluble compounds. In
fact, the most popular approach is incorporation of the drug compound into inert lipid
vehicles such as oils and surfactant dispersions, self-emulsifying formulations (4–6), emul-
sions, liposomes, with particular emphasis on self-microemulsifying drug delivery sys-
tems (SMEDDS) (7).
SEDDS formulations are isotropic mixtures of a drug, lipid, surfactant and a co-sur-
factant or co-solubilizer. The basic principle of this system is its ability to form fine oil-
-in-water (o/w) microemulsions under gentle agitation following dilution by aqueous
phases, i.e., digestive motility of the stomach and intestine provide the agitation requir-
ed for self-emulsification in vivo in the lumen of the gut. This spontaneous formation of
an emulsion in the gastrointestinal tract renders the drug in solubilized form, and the
small size of the formed droplet provides a large interfacial surface area for drug ab-
sorption (8). Apart from solubilization, the presence of lipids in the formulation further
helps improve bioavailability by affecting the drug absorption. Selection of a suitable
self-emulsifying formulation depends upon the assessment of drug solubility in various
components, the area of the self-emulsifying region obtained in the phase diagram, and
the droplet size distribution of the resultant emulsion following self-emulsification (9).
SEDDS formulation offers the opportunity to deliver lipophilic drugs to the gastrointes-
tinal tract in a dissolved state, avoiding the dissolution step (which can limit the absorp-
tion rate of BCS class II and IV drugs), reduction in inter- and intra-subject variability,
reduction of food effect, ease of manufacturing and scale-up, ability to deliver peptides
that are prone to enzymatic hydrolysis in GIT and no influence of lipid digestion process
(10–12).
Albendazole (ABZ, methyl[6-(propylthio)-1H-benzoimidazol-2-yl] carbamate), is a
benzimidazole carbamate broad spectrum oral anthelmetic used to treat a variety of
worm infections caused by nematodes and cestodes (13). ABZ is poorly soluble and its
aqueous solubility is reported to be 0.2 mg mL–1 at 25 °C. It has weak basic properties
(pKa1 = 2.68 and pKa2 = 11.83) and a log P of 3.5 (14). ABZ falls into the BCS class II cate-
gory as has high permeability and low solubility. Because of its low aqueous solubility, it
is poorly and erratically absorbed following oral administration (15). Following oral ad-
ministration to rats, it was found to absorb 20–30 %, whereas in humans the percent ab-
sorbed is 1–5 (16). Following oral administration, ABZ undergoes extensive metabolism
in the intestine and liver (by cytochrome P450 (CYP) 3A4 and/or flavin-containing mono-
oxygenase (FMO) into its major active metabolite, i.e., albendazole sulfoxide (ABZ-SOX)
or ricobendazole (RBZ). RBZ is further metabolized by CYP2C into albendazole sulfone
(ABZ-SON), which is pharmacologically inactive. Due to extensive metabolism in all
species, plasma concentrations of ABZ are usually low compared to the concentrations
of its oxidized metabolites RBZ and ABZ-SON.
Lack of water solubility of any drug reduces its flexibility for drug formulation and
administration. To overcome these drawbacks and to increase aqueous solubility of ABZ,
different formulation approaches have been tried in the past to improve ABZ aqueous
solubility. For instance, since ABZ is basic in nature, its solubility can be increased by
ionization in an acid medium, although this increase in solubility is not sufficient for the
preparation of high-ABZ concentration formulations (17). Another approach involved ad-
dition of surfactants such as Tween 80 and bile salts, or co-solvent agents such as Transcu-
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tol (18–20). Use of liposomes (21) and a solid dispersion approach with polyvinylpyrroli-
done (22–24) showed less promise. Recently, a formulation with a high ABZ concentration
was prepared by complexation with hydroxypropyl-b-cyclodextrin (25, 26). Lately, a lipid
based delivery system of ABZ, the self-microemulsifying drug delivery system (SMEDDS)
for improving ABZ solubility, was published (27).
The main objectives of this study were two-fold: i) to develop and evaluate an opti-
mal SEDDS formulation containing ABZ; ii) to evaluate the SEDDS formulation poten-
tial to improve systemic exposure of ABZ by conducting an oral pharmacokinetic study
in rats. Though an earlier SMEDDS formulation of ABZ was reported and evaluated in
rabbits (27), the increase in AUC and cmax was ~2-fold. Considering the precedence of er-
ratic oral absorption and high pre-systemic metabolism of ABZ following its oral admin-
istration, we feel that ~2-fold improvement is not adequate and sometimes it will not be
truly reflective because of erratic absorption of ABZ. After reviewing the earlier pub-
lished SMEDDS formulation of ABZ (27), we found that the authors did not choose a
suitable combination of excipients to prepare the SMEDDS formulation, which are criti-
cal for forming the droplet size when the SMEDDS formulation is dispersed.
In this paper, we made a systematic evaluation of ABZ solubility and selected the
right oil (Labrafac Lipofile WL1349) and S/CoS (Tween 80/PEG 400) mixture to develop
the SEDDS formulation. We characterized the optimized SEDDS formulation through
the following: stability study, emulsification study and in vitro drug release by dissolu-
tion. We have also determined the droplet size of the emulsion and found that droplets
are in the nanometer range. Having established all the in vitro tests, the SEDDS formula-




ABZ, Tween 80, soya oil, olive oil, sunflower oil, corn oil, propylene glycol were pur-
chased from Sigma Aldrich (Milwaukee, USA). Sesame Labrasol (caprylocaproyl macro-
golglycerides), Labrafac Lipofile WL1349, 1357 and 1358 (medium chain triglycerides),
Capryol PGMC (propylene glycol caprylate), Lauroglycol FCC (propylene glycol laurate)
and Maisine 35-1 (glyceryl monolinoleate) were gift samples from Gattefosse (Mumbai,
India). Capmul PG-8 (propyleneglycol monocaprylate), Captex 300 Low CC (glyceryl
tricaprylate/caprate), Captex 355 (glycerol caprylate caprate) and Capmul MCM (gly-
ceryl mono and dicaprate) were obtained from Abitec Corporation (Columbus, OH, USA).
Poloxamer 188 (ethylene oxide/propylene oxide block copolymer), Cremophor RH40
(polyoxyl 40 hydrogenated castor oil), Lutrol E300 (polyethylene glycol 300), Lutrol E400
(polyethylene glycol 400), Solutol HS15 (polyethylenglycol-660-12-hydroxystearate) and
Cremophor EL (castor oil, ethoxylated) were obtained from BASF (Mumbai, India) through
Signet Corporation. RBZ was procured from Jay Radhe Sales (Ahmedabad, India). Sesame
oil, Span-20 and crodamol GTCC were procured from Croda Chemicals (Mumbai, India).
All other chemicals used were of analytical grade.
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Solubility studies
The solubility experiment was carried out in various oils, surfactants and co-surfac-
tants, by using the 96-well plate format. The DMSO stock was spiked into each excipient
at 500 µg mL–1 concentration. Following spiking, the 96-well plate was kept shaking for
2 h to equilibrate. After equilibration, the plate was centrifuged at 4000 rpm at 37 °C on
a Sigma centrifuge for 10 min. Supernatant was used for HPLC analysis.
Construction of a pseudo-ternary phase diagram
Pseudo-ternary phase diagrams of oil, surfactant/co-surfactant (S/CoS) and water
were developed using the water titration method at room temperature (25 ± 1 °C). Mix-
tures of oil and S/CoS at certain mass ratios were diluted with water in a dropwise man-
ner. For each phase diagram at a specific ratio of S/CoS (2:1 and 3:1), a transparent and
homogenous mixture of oil and S/CoS was formed by vortexing for 5 min. Each mixture
was then titrated with water and visually observed for phase clarity and flowability.
Mixtures of surfactant and co-surfactant with water were prepared at the ratios of 10:0,
9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9 and 0:10. Resulting mixtures were evaluated visually
for transparency and flow properties. Endpoint of titration was the point where the mix-
ture became turbid or phase separation was observed. At that point, the amounts of wa-
ter, oil, surfactant and co-surfactant added were noted. Monophasic, clear, low viscous
systems were considered as micro-emulsion (ME) and shown as the ME region.
Emulsification study
Self-emulsification ability of surfactants was assessed to select the best surfactant
from a large pool of surfactants. Selected oil and surfactants were mixed in 1:3, heated at
40–50 °C and vortexed to form a homogenous mixture at room temperature (25 ± 1 °C).
To evaluate the effect of the co-surfactants on emulsification, the ratio of surfactant to
co-surfactant was kept constant 3:1 and this mixture was mixed with the oil in the ratio
of 3:1 based on the requirements stated by Pouton (2000) (28). Oil-surfactant mixture,
500 mg dispersed in 500 mL of doubly distilled water in a glass beaker, was prepared
under gentle stirring. Visual test was used to assess self-emulsification of surfactants in
terms of dispersability, ease of emulsification and final appearance using a grading sys-
tem (29) (Table I).
Preparation of ABZ SEDDS
A series of SEDDS formulations was prepared using Tween 80, Solutol HS (surfac-
tants), PEG 400, propylene glycol (co-surfactant) and Captex 300 Low C6, Labrafac Lipo-
file WL1349 and Capmul PG8 (oil). In all formulations, the level of ABZ concentration was
kept constant (0.1 %, m/m, of total formulation weight). Drug loading was done on selected
formulations, which were found satisfactory in the emulsification study. The selected oil
and surfactant mixture ratio was 1:3 and surfactant and co-surfactant ratio was 3:1. Drug
loading was done on the basis of m/m of the composite weight of the formulation.
Briefly, SEDDS formulations were prepared so that accurately weighed ABZ was
placed in an Eppendorf tube, dispersed into oil phase and heated at 40–50 °C under vor-
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tex. Surfactant and co-surfactant were mixed together in a separate test tube and mixed
well under vortex. Surfactant and co-surfactant were heated up to 60 °C to mix properly.
Drug containing oil phase was transferred into the surfactant and co-surfactant mixture
under continuous mixing. They were vortex mixed and heated at 50 °C in a sonicator
until ABZ was perfectly dissolved. The azotropic mixture was stored at room tempera-
ture until further use.
In vitro dissolution studies
A quantitative in vitro release test was performed in 500 mL of phosphate buffer pH
6.8 and 0.1 mol L–1 HCl using glass beakers maintained at 37 °C on a magnetic stirrer at
100 rpm. The SEDDS formulation (400 mg) was filled into size-3 hard gelatin capsules
for in vitro dissolution evaluation. Samples were taken at 5, 8, 12 and 15 min time points
for drug release. At each time point, the removed sample volume was replaced with 5
mL of fresh medium. Samples were centrifuged at 4000 rpm for 10 min, filtered using a
0.45 µm syringe filter and analyzed on HPLC.
Emulsion droplet size measurement
An aliquot of 500 µL of each SEDDS formulation was diluted to 250 mL with Milli-
-Q water in a beaker using a magnetic stirrer. The resultant emulsion was then subjected
to particle size analysis using a Malvern Zetasizer (Worchestershire, UK) equipped with
2000 Hydro MU at 25 °C, with a particle size measurement range of 0.02 to 2000 µm.
Particle size was calculated from the volume size distribution.
Freeze-thawing
Freeze-thawing was employed to evaluate the stability of formulations. Thermody-
namic stability was evaluated at different temperatures. To check the effect of tempera-
ture, the formulation was subjected to freeze-thaw cycles (–20 °C, 1–4 °C for 1, 2 and 3
days, followed by 40 °C for 1, 2 and 3 days). Another sample was kept at 40 °C for 1, 2
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Formulation spread rapidly in water, forming a clear and transparent
microemulsion
< 1 A+
Formulation formed a transparent, gel-like intermediate structure
prior to dispersing completely but could form microemulsion
3–5 A
Formulation droplets spread in water to form a turbid emulsion > 5 B
Formulation exhibited poor emulsification with coalescence of oil
droplets
NE C
A+ – rapid microemulsion; A – microemulsion; B – emulsion; C – poor emulsion; NE – no emulsion
and 3 days. At the end of the cycle, the formulation was diluted and centrifuged. Dilu-
tion was 1:10, 1:50, 1:100 and 1:500, followed by centrifugation at 5000 rpm for 10 min.
The formulations were then observed for phase separation. Only formulations that were
stable to phase separation were selected for further studies.
Animals
Male Sprague-Dawley rats were procured from Bioneeds, Bangalore, India. The ani-
mals were housed in the Jubilant Biosys animal care facility in a temperature and hu-
midity controlled room with 12:12 h light/dark cycles, had free access to food (Lipton
India) and water ad libitum. Animal experiments were approved by the Jubilant Biosys
Ltd. Institutional Animal Ethics Committee and were in accordance with the Committee
for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry
of Social Justice and Environment, Government of India.
Oral pharmacokinetic (PK) study
Blood samples were collected following oral administration of ABZ using SMEDDS
(self emulsfying drug delivery system) and conventional suspension (0.5 % methyl cel-
lulose + 0.1 % Tween-80) formulations at a dose of 30 mg kg–1 to overnight fasted (~12 h,
during fasting animals had free access to water) Sprague Dawley rats (n = 4 each group,
189–193 g). Blood samples (100 µL) were collected into polypropylene tubes containing
Na2EDTA solution as an anti-coagulant at pre-dose, 0.25, 0.5, 1, 2, 4, 8 6, 10, 18, 20 and
24 h from retro-orbital plexus.
Plasma collection and processing
From the above PK study blood samples, plasma was harvested by centrifuging the
blood using an Eppendorf 5430R centrifuge (Germany) at 5000 rpm for 5 min. Harvested
plasma was stored frozen at –80 ± 10 °C until analysis. Plasma (50 µL) samples were pro-
cessed as described below.
Plasma sample analysis
Plasma samples were analyzed for simultaneous quantification of ABZ and RBZ us-
ing a validated LC-MS/MS published by us (30). Briefly, to an aliquot of 50 µL plasma
sample, 400 µL of 10 % tetrahydrofuran (THF) in acetonitrile, containing 100 ng mL–1 of
internal standard (phenacetin), was added and samples were centrifuged at 14000 rpm
in 5430R (Eppendorf, Germany) at 10 °C for 10 min. About 400 µL of clear supernatant
was transferred into the sample vial and 10 µL was injected onto the analytical column
for analysis. Resolution of analytes and internal standard was achieved on a Chromolith
Performance, RP-18e (100 x 4.6 mm, Merck, Darmstadt, Germany) column using 5 mM
ammonium acetate (pH 6.0)/acetonitrile (20:80, V/V) as mobile phase delivered at a flow
rate of 1.0 mLmin–1. Tandem mass spectrometric (MS/MS) detection was performed with
a triple quadrupole MDS Sciex (Foster City, CA, USA) API-4000 mass spectrometer equip-
ped with a Turboionspray (ESI) source and the analytes were monitored and quanti-
fied using Analyst software (version 1.5). Detection of ions was performed in the multi-
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ple reaction monitoring (MRM) mode, monitoring the transition of the m/z 266.1
precursor ion to the m/z 234.4 product ion for ABZ, m/z 282.2 precursor ion to the m/z
240.4 product ion for RBZ and m/z 180.1 precursor ion to the m/z 110.1 product ion for IS.
Quadrupole Q1 and Q3 were set to unit resolution. The dwell time was 200 ms. The
method had reproducible linearity over a range of 2.01–2007 and 6.02–6020 ng mL–1 for
ABZ and RBZ, respectively. Along with PK samples, QC samples at low, medium and
high concentration were assayed in duplicate and were distributed among calibrators
and unknown samples in the analytical run. The criteria for acceptance of analytical
runs encompassed the following: i) 67 % of the QC samples accuracy had to be within
85–115 % of the nominal concentration; ii) 50 % of each QC concentration level had to
meet the acceptance criteria.
PK data analysis
Plasma concentration vs. time data of ABZ and RBZ was analyzed by the non-com-
partmental method using WinNonlin Version 5.1 (Pharsight Corporation, Mountain View,




Various oils and surfactants were used in this study. The results of solubility studies
of ABZ in various oils and surfactants are presented in Table II. It is evident from the
data obtained that ABZ does not have good solubility in any of the excipients used. The
highest solubility 498.90 µg g–1 was found in PEG 400. These results concur with those of
Torrado et al., who found low solubility of ABZ in similar solubility enhancers (18). Some
excipients showed a relatively high solubilizing ability, for example, polyethylene glycol
300 (340.45 µg g–1), Lauroglycol FCC (186.05 µg g–1), Cremophor EL (179.76 µg g–1),
Solutol HS15 (193.44 µg g–1), Labrafac Lipofile WL1349 (96.78 µg g–1), Capmul PG-8
(139.88 µg g–1), Span 20 (185.79 µg g–1), Captex 355 (99.37 µg g–1), Labrasol (188.13 µg g–1),
Capryol PGMC (179.48 µg g–1) and Tween 80 (172 µg g–1). Based on these results, Tween
80, Solutol HS15, PEG 400, Captex 300 Low C 6, Labrafac Lipofile WL1349, Propylene
glycol, Lauroglycol FCC and Capmul PG8 were selected for drug loaded SEDDS formu-
lation development. Although some other excipients show good solubility, we have con-
sidered emulsification and drug loading parameters for selection of surfactants and oils
and selected the above listed excipients.
While formulating SEDDS, it is important to avoid precipitation of the drug upon
dilution in the gut lumen in vivo. Therefore, the components used in the formulation of
SEDDS should have a high solubilizing capacity to ensure drug solubilization in the re-
sultant dispersion. From the results of solubility studies, the highest solubility for ABZ
was found in PEG 400 (498.90 µg g–1).
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Construction of a pseudo-ternary phase diagram
In the present study, oil – Labrafac Lipofile WL1349, surfactant – Tween 80 and co-
surfactant – PEG 400 mixture were used. The surfactant to co-surfactant ratios 2:1 and
3:1 were maintained. As seen from the ternary plots (Fig. 1 and 2), Labrafac Lipofile
WL1349 gave a wider microemulsion region when the 3:1 ratio of the surfactant to co-
-surfactant was maintained compared to 2:1.
Upon their introduction into aqueous media, self-emulsifying systems form fine oil-
-water emulsions with only gentle agitation. Surfactant and co-surfactant get preferen-
tially adsorbed at the interface, reducing the interfacial energy as well as providing a
mechanical barrier to coalescence. Decrease in the free energy required for emulsion for-
mation consequently improves the thermodynamic stability of the microemulsion for-
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mulation (34, 35). Therefore, the selection of oil and surfactant, and the mixing ratio of
oil to S/CoS, play an important role in the microemulsion formation. The phase diagram
was constructed using Labrafac Lipofile WL1349 as oil, Tween 80 as surfactant and PEG
400 as co-surfactant. From the results of the phase diagram, the selected surfactant to
co-surfactant ratio is 3:1 and 1:3 for oil to S/Co-S because the microemulsion is formed
in this region. These data are supported by the phase diagram (28).
Emulsification study
Emulsification grading for relative emulsification of surfactants is shown in Table I. It
clearly distinguishes the ability of surfactants to emulsify selected oily phases. The results
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Fig. 1. Ternary phase diagram prepared with oil-Labrafac Lipofile WL1349, surfactant-Tween 80 and
co-surfactant PEG400 (S/CoS ratio 3:1).
Fig. 2. Phase diagram prepared with oil-Labrafac Lipofile WL1349, surfactant-Tween 80, and co-
surfactant PEG400 (S/CoS ratio 2:1).
of emulsification with different oils and surfactants are summarized in Table III and the
effects of the co-surfactant results are summarized in Table IV using the grading system.
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Tween C A+ A+ A A+ A+ D A A+
Gelucire 44/14 D D D C C A+ D C A+
Creomophor
EL
D C C A B A+ C A A+
Labrasol C C C C C D C C C
Cremophore
RH 40
C A+ A+ A+ A A+ A+ A A+
Acrysol K150 C A+ A+ A A A+ C A A+
Solutol HS15 D C A+ A+ A+ A+ D A+ A+
A+ – rapid microemulsion; A – microemulsion; B – emulsion; C – poor emulsion; D – no emulsion







Tween 80 + PEG400 A+ A+ A+
Tween 80 + Lauroglycol FCC C B C
Tween 80 + Propylene glycol A+ A+ A+
Cremophore EL+ PEG400 A A+ A+
Cremophore EL+ Lauroglycol FCC A+ A A+
Cremophore EL+ Propylene glycol A+ A+ A+
Acrysol K150 + PEG400 A+ A+ A+
Acrysol K150 + Lauroglycol FCC A+ A+ A+
Acrysol K150 + Propylene glycol A+ A+ A+
Solutol HS15 + PEG400 A A+ A+
Solutol HS15 + Lauroglycol FCC A A+ C
Solutol HS15 + Propylene glycol A+ A+ A
A+ – rapid microemulsion; A – microemulsion; B – emulsion; C – poor emulsion; D – no emulsion
Although HLB values of surfactants used in study were > 10, there were consider-
able differences in their ability to emulsify oils. The results obtained indicated that apart
from the HLB value, other factors such as structure and relative length of hydrophobic
chains of surfactants influenced microemulsification. These results are in agreement
with the results reported in literature (36, 37). Cremophor EL and Tween 20 rendered ef-
fective microemulsification and were selected for further study. Among the oils, soya oil
and olive oil were difficult to emulsify, followed by Capmul MCM, Maisine 35-1, Captex
300 Low, Labrafac Lipofile WL1349, Capryol PGMC, Captex 355 low and Capmul PG8,
which were emulsified easily. This is explained by fact that the ease of oil emulsification
and the amount incorporated in microemulsion are affected by the molecular volume of
oil. As the number and length of hydrophobic alkyl chains increases, molecular volume
increases. These observations are in line with studies reported by Warisnoicharoen et al.
(38) and Malcolmson et al. (39). Labrafac Lipofile WL1349 provides good emulsion com-
pared to other oils; the oil HLB value was near 1.0, so it has a high lipophilic nature and
can load more of the compound. We have selected them as oily phases for further study
due to their relative ease of self-microemulsification. Emulsification capacities of the
surfactants were also evaluated with the above oils from Table III, all surfactants show-
ing good emulsification power except Labrasol, which has a low HLB value compared
to other oils. Table IV shows relative efficacy of co-surfactants of improving the
emulsification of surfactants. PEG 400 and Lauroglycol FCC were used as co-surfactants
and Tween 80, Cremophore EL and Acrysol K 150 were used as surfactants. All combi-
nations increased the spontaneity of microemulsion formation. As the ratio of surfactant
to co-surfactant was constant, the study clearly distinguished the ability of co-surfac-
tants to improve the emulsification of surfactants. Furthermore, as co-surfactants im-
prove emulsification of surfactants by penetrating the interfacial surfactant monolayer,
their performance is affected by their structure and chain length. Thus, the study gave
an insight into relative emulsification properties of SEDDS components and forms the
basis for their selection as selected excipients.
Preparation of ABZ SEDDS
A series of SEDDS formulations was prepared using Tween 80, Solutol HS15 as sur-
factant; PEG 400, Propylene glycol, as co-surfactant, and Captex 300 Low C6, Labrafac
Lipofile WL1348, Capumul PG-8 as oil phase. All formulations were able to take a load
of 0.1 % ABZ and were homogenous and transparent. ABZ was completely in soluble
form. Combinations of all formulations are given in Table V.
In vitro evaluation of formulations
In vitro dissolution of ABZ SEDDS was done in 0.1 mol L–1 HCl and phosphate
buffer pH 6.8. The release of ABZ in all different drug loaded formulations was checked.
Release of ABZ in all formulations was over 90 % in 10 min both in phosphate buffer pH
6.8 and 0.1 mol L–1 HCl. The results are shown in Figs. 3 and 4.
ABZ has low solubility and dissolution rate in conventional formulations (14). Us-
ing the proposed formulation approach, we were able to attain more than 90 % release in
10 min in both dissolution media. These results indicate that SEDDS formulation re-
sulted in spontaneous formation of a microemulsion with a small droplet size, which
permitted a faster rate of ABZ release in dissolution media. As the drug is present in dis-
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solved state, the dissolution step is omitted for the GI tract, which permits faster release
of the drug into aqueous phase, which could affect oral bioavailability.
The average droplet size of the selected formulation was obtained as Z-average
127.5 and PDI 0.264 nm. Three peaks in Fig. 5 indicate that three different sizes of drop-
lets existed in the formulation, all droplets sizes being in nanometers, peak 1 (29.94 nm),
peak 2 (283.2 nm) and peak 3 (75.2 nm). Their corresponding intensity was 57.1, 37.2 and
10.3 %, respectively, indicating that major droplets were 29.94 nm. Nanometer particle
size of droplets after emulsification was the most important property of SEDDS.
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Surfactant 56.25 Tween 80
Co-surfactant 18.75 PEG 400
Fig. 3. Dissolution profile of albendazole formulation in pH 6.8 phosphate buffer.
Freeze-thawing
The freeze-thaw cycling test was performed to test the robustness of the formula-
tion. One freeze-thaw cycle consisted of microemulsion storing at –20 °C, 1–4 °C for 24,
48 and 72 h. After this, formulations were stored at 40 °C for another 24, 48 and 72 h. No
phase separation of the ABZ loaded SEDDS formulation was observed upon
centrifugation. However, the thermal cycling study created a thermodynamically unsta-
ble microemulsion, which had larger droplet size distribution upon dilution. Visual ob-
servation indicated that there was no phase separation in any formulation and the physi-
cal appearance of all formulations was similar.
The thermal cycling study created a thermodynamically unstable microemulsion,
which had larger droplet size distribution upon dilution. Visual observation indicated that
there was no phase separation in all formulation and the physical appearance of all for-
mulations was similar. This study has revealed that a sudden change in temperature
causes a change in the entropy of the system, which results in coalescence of droplets. The
overall stability of the formulation under normal conditions was found to be acceptable.
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Fig. 5. Particle size distribution of the selected albendazole microemulsion by Zetasizer.
Fig. 4. Dissolution profile of albendazole formulation in 0.1 mol L–1 HCl.
Oral pharmacokinetic (PK) study
Due to extensive metabolism, plasma concentrations of ABZ are usually low and it
has been already reported that RBZ is the active metabolite of ABZ; we have quantified
both ABZ and RBZ simultaneously using a validated method published by us (30). In
fact, it was reported that pharmacokinetics of ABZ had been studied by determining the
plasma concentrations of RBZ and ABZ-SON (31–33). From the results of two studies
[i.e., suspension vs. SEDDS] it was evident that the SEDDS formulation increased both
cmax and AUC of ABZ and its active metabolite, i.e., RBZ. The PK parameter results for
ABZ and RBZ are shown in Table VI. Time vs. plasma concentration for ABZ and RBZ is
shown in Fig. 6. Following ABZ suspension formulation, both ABZ and RBZ (formed
from ABZ) were seen only up to 10 h, whereas following SEDDS formulation adminis-
tration of ABZ, ABZ and RBZ (formed from RBZ) were seen up to 18 and 20 h, respec-
tively.
Elimination half-life (t½,ß) observed for ABZ after dosing of suspension formulation
was 2.61 h, while extended t½,ß of 1.78 h was observed for the SEDDS formulation profile.
Peak concentration was found to be 6-fold higher for SEDDS formulation, i.e., cmax value
of 309 ng mL–1 for suspension formulation vs. 1876 ng mL–1 for SEDDS formulation. Ex-
posure was found to be 11-fold higher for SEDDS formulation, i.e., AUC0-t value of 980 ng
h mL–1 for suspension formulation vs. 11167 ng h mL–1 for SEDDS formulation.
Elimination half-life (t½,ß) observed for RBZ after dosing of ABZ suspension formu-
lation was 4.71 h, while lower t½,ß of 1.36 h was observed for the SEDDS formulation
profile. Peak concentration was found to be 3.7-fold higher for SEDDS formulation i.e.,
cmax value of 2.410 mg mL–1 for suspension formulation vs. 8.976 mg mL–1 for SEDDS for-
mulation. Exposure was found to be 6-fold higher for SEDDS formulation, i.e., AUC0-t
value of 16.904 mg h mL–1 for suspension formulation vs. 99.962 mg h mL–1 for SEDDS
formulation. Lower t½,ß was attributed to rapid elimination and inadequate elimination
phase time points (as the concentration of RBZ was 7.025 mg mL–1 at 10 h and decreased
to 4.55 ng mL–1 at 24 h post dose).
Increase in exposure was evident for both ABZ and its active metabolite RBZ from
the results obtained in pharmacokinetic studies. SEDDS formulation clearly proved to
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Table VI. Pharmacokinetic parameters of ABZ and RBZ (released from ABZ) following oral administration
of albendazole suspension and SEDDS formulations at 30 mg kg–1 to Sprague Dawley rats
PK parameter Albendazole (ABZ) Ricobendazole (RBZ)
Suspension SEDDS Suspension SEDDS
AUC0-t (ng h mL–1) 980 ± 527 11167 ± 1666 16904 ± 7314 99962 ± 6334
AUC0-8 (ng h mL–1) 1024 ± 557 11448 ± 1359 23740 ± 12440 100517 ± 6993
cmax (ng mL–1) 309 ± 96 1876 ± 281 2410 ± 906 8976 ± 752
tmax (h) 1.00 ± 0.71 1.75 ± 1.50 3.00 ± 1.15 6.00 ± 2.13
t½, (h) 2.61 ± 0.99 1.78 ± 0.57 4.71 ± 1.13 1.36 ± 0.21
a n = 4
be superior over the conventional suspension formulation strategy and could provide a
step forward for the design of PK studies of such poorly soluble and rapidly metaboliz-
ing molecules.
CONCLUSIONS
An optimized self-emulsifying drug delivery system for ABZ was successfully de-
veloped, with an increased dissolution rate and solubility compared to conventional for-
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Fig. 6. Plasma concentration vs. time profiles for ABZ and RBZ (released from ABZ) following oral
administration of ABZ suspension and SEDDS formulations at 30 mg kg–1 to Sprague Dawley rats
(n = 4).
mulations, which ultimately increased the systemic exposure of ABZ and its active me-
tabolite RBZ in rats. Our study illustrated the potential of using SEDDS to dispense
poorly water-soluble drug by oral route.
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S A @ E T A K
Razvoj samoemulzifiraju}eg sustava za isporuku albendazola (SEDDS)
s poja~anom sistemskom apsorpcijom
ASHOK K. MEENA, KULDEEP SHARMA, MURUGESH KANDASWAMY, SRIRAM RAJAGOPAL i RAMESH MULLANGI
Cilj rada bio je razvoj i evaluacija samoemulzifiraju}eg sustava za isporuku lijekova
(SEDDS) pove}ane topljivosti i osloba|anja, te pove}ane sistemske apsorpcije anthelminti-
ka albendazola (ABZ), lijeka iz klase BCS II. Odabir sastojaka za pripravu mikroemulzija
izvr{en je na temelju topljivosti albendazola u razli~itim uljima, surfaktantima i kosurfak-
tantima. Kako bi se odredilo podru~je u kojem dolazi do mikroemulzifikacije izra|eni su
pseudoternarni fazni dijagrami. SEDDS formulacija albendazola pripravljena je pomo}u
smjese ulja (Labrafac Lipopfile WL1349) i surfaktanta/kosurfaktanta (Tween 80/PEG-400).
Dobivenom pripravku odre|ena su mikroemulzifiraju}a svojstva, veli~ina kapljica, oslo-
ba|anje in vitro, itd. Osim toga, odre|eni su farmakokineti~ki parametri za ABZ SEDDS u
{takora i uspore|eni sa suspenzijom albendazola. Zaklju~eno je da se pomo}u SEDDS-a
mo`e pove}ati topljivost i sistemska apsorpcija lijekova slabo topljivih u vodi kao {to je
ABZ.
Klju~ne rije~i: albendazol, pripravak na bazi lipida, SEDDS, farmakokinetika, {takori
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